We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET
226
DELISTED
Aceto Corp
ACET
– –
-6,054
Closed -$115K
AET
227
DELISTED
Aetna Inc
AET
– –
-4,454
Closed -$514K
KND
228
DELISTED
Kindred Healthcare
KND
– –
-42,301
Closed -$432K
ANTH
229
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-182,453
Closed -$4.6M
IPXL
230
DELISTED
Impax Laboratories, Inc.
IPXL
$0 ﹤0.01%
+1
New +$17
CGNT
231
DELISTED
Cogentix Medical, Inc.
CGNT
– –
-99,008
Closed -$180K
VWR
232
DELISTED
VWR Corporation
VWR
– –
-18,657
Closed -$529K
AMRI
233
DELISTED
Albany Molecular Research Inc
AMRI
– –
-10,300
Closed -$170K
AMSG
234
DELISTED
Amsurg Corp
AMSG
– –
-6,618
Closed -$444K
AFAM
235
DELISTED
Almost Family Inc
AFAM
– –
-11,942
Closed -$439K
DSCI
236
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-2,970
Closed -$14K
WOOF
237
DELISTED
VCA Inc.
WOOF
– –
-7,940
Closed -$556K
6 7 8 9
10

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.